Predictive Oncology Announces Closing of $7.4 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules
February 16, 2021 17:00 ET
|
Predictive Oncology Inc.
MINNEAPOLIS, Feb. 16, 2021 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI) (“Predictive Oncology” or “the Company”), a knowledge-driven company focused on applying artificial...
Predictive Oncology Announces $7.4 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
February 11, 2021 00:30 ET
|
Predictive Oncology Inc.
MINNEAPOLIS, Feb. 10, 2021 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI) (“Predictive Oncology” or “the Company”), a knowledge-driven company focused on applying artificial...
Predictive Oncology’s Wholly Owned Subsidiary Helomics announces the start of its drug repurposing project using its ground-breaking PeDAL™ platform for ovarian cancer
February 08, 2021 08:30 ET
|
Predictive Oncology Inc.
MINNEAPOLIS, Feb. 08, 2021 (GLOBE NEWSWIRE) -- Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug...
Predictive Oncology Has Regained Compliance with Nasdaq’s Minimum Bid Price Requirement
February 02, 2021 12:00 ET
|
Predictive Oncology Inc.
MINNEAPOLIS, Feb. 02, 2021 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI) (“Predictive Oncology” or “the Company”), a knowledge-driven company focused on applying artificial...
Litchfield Hills Research Rates Predictive Oncology a Buy on Recent Analyst Report
February 02, 2021 08:30 ET
|
Predictive Oncology Inc.
MINNEAPOLIS, Feb. 02, 2021 (GLOBE NEWSWIRE) -- Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug...
Soluble Biotech, a Wholly Owned Subsidiary of Predictive Oncology, Inked Contract with Large Pharmaceutical Company
January 28, 2021 08:30 ET
|
Predictive Oncology Inc.
MINNEAPOLIS, Jan. 28, 2021 (GLOBE NEWSWIRE) -- Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug...
Predictive Oncology Announces Closing of $4.1 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules
January 26, 2021 21:00 ET
|
Predictive Oncology Inc.
MINNEAPOLIS, Jan. 26, 2021 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI) (“Predictive Oncology” or “the Company”), a knowledge-driven company focused on applying artificial...
Predictive Oncology Announces $4.1 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
January 22, 2021 08:00 ET
|
Predictive Oncology Inc.
MINNEAPOLIS, Jan. 22, 2021 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI) (“Predictive Oncology” or “the Company”), a knowledge-driven company focused on applying artificial...
Predictive Oncology Announces Closing of $2.2 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules
January 21, 2021 17:25 ET
|
Predictive Oncology Inc.
MINNEAPOLIS, Jan. 21, 2021 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI) (“Predictive Oncology” or “the Company”), a knowledge-driven company focused on applying artificial...
Predictive Oncology Announces $2.2 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
January 19, 2021 08:00 ET
|
Predictive Oncology Inc.
MINNEAPOLIS, Jan. 19, 2021 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI) (“Predictive Oncology” or “the Company”), a knowledge-driven company focused on applying artificial...